B · Normal
[Bristol-Myers Squibb Announces Preliminary Phase III Clinical Data of KarXT in the Treatment of Alzheimer's Disease-Related Psychosis] On November 18, Bristol-Myers Squibb (BMY) announced preliminary data from two phase III studies of the ADEPT project to evaluate the effect of the drug KarXT (xanomeline and trospium chloride) in the treatment of Alzheimer's disease-related psychosis. In the ADEPT-1 study, 273 of 320 enrolled patients completed the 12-week open-label treatment, with a completion rate of 85.3%; the patients' hallucinations and delusions score (NPI-C H+D) decreased by an average of 12.0 points from baseline to 14.4 points, and the clinical global severity score (CGI-S) decreased by an average of 1.9 points from a baseline of 4.5 points. In the ADEPT-3 study, 273 of 401 patients completed 52 weeks of treatment, with a completion rate of 68.1%; no new safety signals were found during treatment. The company stated that the double-blind treatment phase data of the two studies are still blinded, and the above results are preliminary descriptive analyses.
Comments